title: Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.
abstract: Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNbeta-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFNbeta-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFNbeta-1b was administered to still-active secondary progressive MS. IFNbeta-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFNbeta-1b still remains a first-line therapy with a fundamental role in all stages of the disease.
authors.affiliation: Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy.
authors.forename: Damiano
authors.initials: D
authors.lastname: Paolicelli
authors.forename: Vita
authors.initials: V
authors.lastname: Direnzo
authors.forename: Maria
authors.initials: M
authors.lastname: Trojano
references.citation: J Exp Med. 1995 Nov 1;182(5):1517-25
references.pmid: 7595221
references.citation: Clin Neurol Neurosurg. 2004 Jun;106(3):255-8
references.pmid: 15177779
references.citation: Ann Neurol. 1997 May;41(5):669-74
references.pmid: 9153530
references.citation: Ann Neurol. 1996 Dec;40(6):853-63
references.pmid: 9007090
references.citation: J Neuroimmunol. 1996 Jul;67(2):111-8
references.pmid: 8765333
references.citation: J Interferon Res. 1993 Oct;13(5):333-40
references.pmid: 8301153
references.citation: J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50
references.pmid: 16170501
references.citation: Proc Natl Acad Sci U S A. 1984 Sep;81(18):5662-6
references.pmid: 6091102
references.citation: J Neurol Sci. 2009 Feb 1;277 Suppl 1:S19-24
references.pmid: 19200860
references.citation: Neurology. 2003 Jan 14;60(1):37-43
references.pmid: 12525715
references.citation: Ann Neurol. 1983 Mar;13(3):227-31
references.pmid: 6847134
references.citation: Ann Neurol. 1990 Feb;27(2):207-10
references.pmid: 2138445
references.citation: Neurology. 2008 Mar 25;70(13 Pt 2):1119-27
references.pmid: 18272865
references.citation: Neurology. 1999 Apr 12;52(6):1277-9
references.pmid: 10214759
references.citation: Drug Saf. 2000 Feb;22(2):149-59
references.pmid: 10672896
references.citation: Neurology. 1993 Apr;43(4):655-61
references.pmid: 8469318
references.citation: Pharm Res. 1993 Apr;10(4):567-72
references.pmid: 8483840
references.citation: Clin Pharmacokinet. 1990 Nov;19(5):390-9
references.pmid: 1702693
references.citation: Neurology. 2005 Jul 12;65(1):40-7
references.pmid: 16009883
references.citation: Arch Neurol. 2007 Sep;64(9):1292-8
references.pmid: 17846268
references.citation: Neurology. 2006 Apr 11;66(7):1056-60
references.pmid: 16510769
references.citation: Neurology. 2001 Dec 11;57(11):1969-75
references.pmid: 11739811
references.citation: Ann Neurol. 2005 Dec;58(6):840-6
references.pmid: 16283615
references.citation: Lancet. 2001 May 19;357(9268):1576-82
references.pmid: 11377645
references.citation: Neurology. 2006 Oct 10;67(7):1242-9
references.pmid: 16914693
references.citation: N Engl J Med. 1998 Jan 29;338(5):278-85
references.pmid: 9445407
references.citation: Neurology. 1999 Nov 10;53(8):1622-7
references.pmid: 10563602
references.citation: Neurology. 1998 May;50(5):1294-300
references.pmid: 9595977
references.citation: Arch Neurol. 2001 Jan;58(1):65-70
references.pmid: 11176938
references.citation: Ann Neurol. 2004 Apr;55(4):458-68
references.pmid: 15048884
references.citation: Lancet. 1998 Nov 7;352(9139):1491-7
references.pmid: 9820296
references.citation: J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51
references.pmid: 17986500
references.citation: J Int Med Res. 2007 Mar-Apr;35(2):173-87
references.pmid: 17542405
references.citation: Neurology. 1996 Oct;47(4):889-94
references.pmid: 8857714
references.citation: J Neurol. 2008 Apr;255(4):480-7
references.pmid: 18004635
references.citation: Lancet. 2007 Aug 4;370(9585):389-97
references.pmid: 17679016
references.citation: Neurology. 1995 Jul;45(7):1277-85
references.pmid: 7617182
references.citation: Neurology. 1993 Apr;43(4):662-7
references.pmid: 8469319
references.citation: Brain. 2002 Oct;125(Pt 10):2202-12
references.pmid: 12244078
references.citation: Lancet. 2002 Apr 27;359(9316):1453-60
references.pmid: 11988242
references.citation: J Neuroimmunol. 1993 Jul;46(1-2):145-53
references.pmid: 8360326
references.citation: Ann Neurol. 2007 Apr;61(4):300-6
references.pmid: 17444502
references.citation: Lancet. 2003 Oct 11;362(9391):1184-91
references.pmid: 14568740
references.citation: Mult Scler. 2004 Apr;10(2):126-38
references.pmid: 15124756
references.citation: N Engl J Med. 2000 Sep 28;343(13):898-904
references.pmid: 11006365
references.citation: Neurology. 2004 Mar 9;62(5):719-25
references.pmid: 15007120
references.citation: Ann Neurol. 1996 Dec;40(6):846-52
references.pmid: 9007089